To determine the value of treatments for multiple myeloma (MM), healthcare professionals must evaluate supporting clinical evidence. Such evaluation requires an understanding of the predictive power of specific clinical end points. In other words, it is important to know whether the parameters that a study measures, such as response rate, progression-free survival (PFS), or overall survival (OS), provide a meaningful guide to the expected performance of a treatment in clinical practice. An ongoing topic of controversy in myeloma is the utility of PFS as an end point for guiding treatment decisions.
Last modified: March 7, 2019